AAVB-039 shows promise in Stargardt Disease with ongoing safety and efficacy study
The 039-101 study is evaluating the safety and tolerability of AAVB-039 in Stargardt disease patients.
Asset / Drug
Drug and asset intelligence for AAVB-039 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.